These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 11549985)

  • 41. Economic considerations of the diagnosis and management for glaucoma in the developed world.
    Tuulonen A
    Curr Opin Ophthalmol; 2011 Mar; 22(2):102-9. PubMed ID: 21192264
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Update on the management of glaucoma.
    Haik GM; Terrell WL; Haik GM
    J La State Med Soc; 1989 Oct; 141(10):37-42. PubMed ID: 2600525
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expectations from clinical trials: results of the Early Manifest Glaucoma Trial.
    Lichter PR
    Arch Ophthalmol; 2002 Oct; 120(10):1371-2. PubMed ID: 12365917
    [No Abstract]   [Full Text] [Related]  

  • 44. Betaxolol, Brimonidin and Carteolol in the Therapy of Normal-Tension Glaucoma.
    Lešták J; Fůs M; Weissová I; Marešová K
    Cesk Slov Oftalmol; 2020; 76(2):94-97. PubMed ID: 33126804
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Economics of selective laser trabeculoplasty as primary therapy for glaucoma.
    Buys YM
    Can J Ophthalmol; 2006 Aug; 41(4):419-20. PubMed ID: 16883356
    [No Abstract]   [Full Text] [Related]  

  • 46. Cost analysis of early trabeculectomy versus conventional management in primary open angle glaucoma.
    Ainsworth JR; Jay JL
    Eye (Lond); 1991; 5 ( Pt 3)():322-8. PubMed ID: 1955055
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Betaxolol for hypertension.
    Med Lett Drugs Ther; 1990 Jun; 32(821):61-2. PubMed ID: 1973258
    [No Abstract]   [Full Text] [Related]  

  • 48. The economic implications of glaucoma: a literature review.
    Schmier JK; Halpern MT; Jones ML
    Pharmacoeconomics; 2007; 25(4):287-308. PubMed ID: 17402803
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Cost-effectivity analysis of the most used antiglaucoma drugs].
    Galindo-Ferreiro A; Sánchez-Tocino H; Fernández-Muñoz M; Iglesias Cortiñas D
    Arch Soc Esp Oftalmol; 2004 Aug; 79(8):379-84. PubMed ID: 15306964
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Initial treatment for open-angle glaucoma- medical, laser or surgical? Medication is the treatment of choice for chronic open-angle glaucoma.
    Higginbotham EJ
    Arch Ophthalmol; 1998 Feb; 116(2):239-40. PubMed ID: 9488279
    [No Abstract]   [Full Text] [Related]  

  • 51. Medical predictive factors of glaucoma treatment costs.
    Denis P; Lafuma A; Berdeaux G
    J Glaucoma; 2004 Aug; 13(4):283-90. PubMed ID: 15226656
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Managed care implications of age-related ocular conditions.
    Cardarelli WJ; Smith RA
    Am J Manag Care; 2013 May; 19(5 Suppl):S85-91. PubMed ID: 23725500
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Medical Costs of and Changes in Glaucoma Treatment among Patients Newly Starting Glaucoma Care.
    Fukuda Y; Kume A; Kashiwagi K
    Curr Eye Res; 2021 Nov; 46(11):1695-1702. PubMed ID: 33843390
    [No Abstract]   [Full Text] [Related]  

  • 54. Modeling complex treatment strategies: construction and validation of a discrete event simulation model for glaucoma.
    van Gestel A; Severens JL; Webers CA; Beckers HJ; Jansonius NM; Schouten JS
    Value Health; 2010; 13(4):358-67. PubMed ID: 20659272
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current Knowledge and Attitudes Concerning Cost-Effectiveness in Glaucoma Pharmacotherapy: A Glaucoma Specialists Focus Group Study.
    Feldman RM; Cioffi GA; Liebmann JM; Weinreb RN
    Clin Ophthalmol; 2020; 14():729-739. PubMed ID: 32184559
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Betaxolol (lokren) in arterial hypertension].
    Moiseev VS; Moiseev SV
    Ter Arkh; 1998; 70(2):82-5. PubMed ID: 9551584
    [No Abstract]   [Full Text] [Related]  

  • 57. Additive effect of betaxolol and epinephrine in primary open angle glaucoma.
    Bloom HR; Cech JM; Eston AB; Finegan JT; Gingold MP; Meyer L; Varr WF; Weinberg DA; Wilson C; Zalta AH
    Arch Ophthalmol; 1987 Oct; 105(10):1317-8. PubMed ID: 3662896
    [No Abstract]   [Full Text] [Related]  

  • 58. Assessing the economic value of antihypertensive medicines.
    Drummond M; Coyle D
    J Hum Hypertens; 1992 Dec; 6(6):495-501. PubMed ID: 1296016
    [No Abstract]   [Full Text] [Related]  

  • 59. Comment on 'What is the direct cost of treatment of acute primary angle closure glaucoma? The Singapore model'.
    Papalkar D; Francis IC; Lim R
    Clin Exp Ophthalmol; 2005 Aug; 33(4):446; author reply 447. PubMed ID: 16033375
    [No Abstract]   [Full Text] [Related]  

  • 60. Periocular cutaneous pigmentary changes associated with topical betaxolol.
    Arnoult L; Bowman ZL; Kimbrough RL; Stewart RH
    J Glaucoma; 1995 Aug; 4(4):263-7. PubMed ID: 19920684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.